|Dr. Cameron Geoffrey McDonough||Pres, CEO, Sec. & Director||515.83k||N/A||1970|
|Dr. Matthew Norkunas M.B.A., M.D.||Chief Financial Officer||264.36k||N/A||1978|
|Dr. Tracy Zimmermann Ph.D.||Chief Devel. Officer||342.96k||N/A||1970|
|Dr. Robert Kotin Ph.D.||Co-Founder & Advisor||N/A||N/A||1956|
|Dr. Matthew Stanton Ph.D.||Chief Scientific Officer||N/A||N/A||1973|
|Dr. Jennifer Elliott Esq., J.D., Ph.D.||Chief Legal Officer||N/A||N/A||N/A|
|Ms. Sara Den Besten||Chief People Officer||N/A||N/A||N/A|
|Dr. Douglas Kerr M.B.A., M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1967|
|Ms. Antoinette Paone M.B.A., M.S.||Sr. VP & Head of Regulatory Affairs and Quality||N/A||N/A||N/A|
|Ms. Leslie Wolfe Ph.D.||Sr. VP of Chemistry, Manufacturing & Control||N/A||N/A||N/A|
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.